Literature DB >> 35044633

Evaluation of early clinical failure criteria in Enterococcus species bloodstream infection.

Caroline E Powers1,2, P Brandon Bookstaver3,4, Celeste Caulder3,4, Abigail Bouknight3, Julie Ann Justo3,4, Joseph Kohn3, Hana Rac Winders3, Majdi N Al-Hasan5.   

Abstract

PURPOSE: Early clinical failure criteria (ECFC) were recently introduced to predict unfavorable outcomes in patients with Gram-negative bloodstream infections (BSI). ECFC include hypotension, tachycardia, tachypnea or mechanical ventilation, altered mental status, and leukocytosis evaluated at 72-96 h after BSI. The aim of this retrospective cohort study was to assess performance of ECFC in predicting 28-day mortality in Enterococcus species BSI.
METHODS: Hospitalized adults with Enterococcus species BSI at Prisma Health hospitals from 1 January 2015 to 31 July 2018 were identified. Multivariate logistic regression was used to determine the association between ECFC and 28-day mortality. Area under the receiver operating characteristic (AUROC) curve was used to measure model discrimination.
RESULTS: Among 157 patients, 28 (18%) died within 28 days of BSI. After adjustments in multivariate model, the risk of 28-day mortality increased in the presence of each additional ECFC (OR 1.6, 95% CI 1.2-2.3, p = 0.005). Infective endocarditis (OR 3.9, 95% CI 1.4-10.7, p = 0.01) was independently associated with 28-day mortality. AUROC curve of ECFC model in predicting 28-day mortality was 0.74 with ECFC of 2 identified as the best breakpoint. Mortality was 8% in patients with ECFC < 2 compared to 33% in those with ECFC ≥ 2 (p < 0.001).
CONCLUSION: ECFC had good discrimination in predicting 28-day mortality in patients with Enterococcus species BSI. These criteria may have utility in future clinical investigations.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Antibiotics; Bacteremia; Clinical failure; Enterococcus spp.; Outcomes; Survival

Mesh:

Year:  2022        PMID: 35044633     DOI: 10.1007/s15010-022-01754-6

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   7.455


  1 in total

Review 1.  When are Oral Antibiotics a Safe and Effective Choice for Bacterial Bloodstream Infections? An Evidence-Based Narrative Review.

Authors:  Andrew J Hale; Graham M Snyder; John W Ahern; George Eliopoulos; Daniel Ricotta; W Kemper Alston
Journal:  J Hosp Med       Date:  2018-02-28       Impact factor: 2.960

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.